June 1 2020

Diverse Populations Necessitate Innovative Combinations in Ovarian Cancer

June 20, 2020

Clinical Articles

“We are starting to see more and more patients with recurrent ovarian cancer, we’re treating them much more aggressively in the up-front setting, and we have to face PARP inhibitor resistance in the future.”

Comorbid Toxicities Can Cloud Differential Diagnosis for Immune-Related AEs

June 29, 2020

Clinical Articles

A review of selected trials looking at frequencies of grade 3 irAEs suggests that renal and bone marrow toxicities occur more frequently with the use of PD-1 and PD-L1 inhibitors compared with agents blocking CTLA-4

Global Pandemic Paves Way to Modernize Clinical Trials

June 20, 2020

Clinical Articles

“We’ve seen remote data monitoring and remote data capturing. We are in a situation to continue moving forward, even in the midst of the pandemic, and, in fact, accelerate our position."

HITTING THE TARGET: Multigene Tests Gain Foothold in More Clinical Settings

June 29, 2020

Clinical Articles

Broad adoption of testing methods that allow for assessing all possible actionable targets and diagnostic markers in advanced cancer is becoming more complex with greater availability of lifesaving targeted therapies.

Investigators Employ a Range of Novel and Established Systemic Therapies for Advanced Glioblastoma

June 22, 2020

Treatment of glioblastoma has seen few advancements since the approval of temozolomide plus radiotherapy in 2005 for newly diagnosed disease. Recently, promising clinical data have reinvigorated hope for novel therapies in this tumor type.

Neoadjuvant Therapy Impresses in I-SPY 2 Trial for Breast Cancer

July 04, 2020

According to investigators on the phase 2 I-SPY 2 study, the addition durvalumab plus olaparib to treatment with neoadjuvant paclitaxel led to better pathologic complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer compared with paclitaxel alone.

Addressing Skin-Related Toxicities Extends Positive Clinical Outcomes

June 19, 2020

Management of treatment-associated dermatologic adverse events that commonly occur as a result of cytotoxic or targeted therapy is critical to prevent dose modifications or interruptions that could negatively affect clinical outcomes.